Related Experiment Video
Updated: Apr 28, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
ERK1/2-Egr-1 Signaling Pathway-Mediated Protective Effects of Electroacupuncture in a Mouse Model of Myocardial
Juan Zhang1, Jiangang Song1, Jin Xu1
1Department of Anesthesiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Road, Shanghai 200127, China.
Abstract:
Early growth response- (Egr-) 1 is an upstream master switch in controlling inflammatory responses following myocardial ischemia-reperfusion (I/R). Activation of extracellular signal-regulated protein kinase-1 and kinase-2 (ERK1/2) signaling is known to upregulate Egr-1. ERK1/2 pathway has been previously shown to mediate the therapeutic action of electroacupucture (EA). Thus, we hypothesized that EA would reduce myocardial I/R injury and inflammatory responses through inhibiting Egr-1 expression via the ERK1/2 pathway. Mice were pretreated with EA, U0126, or combination of EA and U0126 and then underwent 1 h myocardial ischemia and 3 h reperfusion. We investigated that EA significantly attenuated the I/R-induced upregulation of both Egr-1 and phosporylated-ERK1/2 (p-ERK1/2), decreased myocardial inflammatory cytokines including tumor necrosis factor- α (TNF- α ) and interleukin-1 β (IL-1 β ), and reduced the infarct size and the release of cardiac troponin I (cTnI). U0126 treatment also exhibited the same effect as EA on Egr-1 level and subsequent cardioprotective effects. There was no additive effect of cotreatment with EA and U0126 on the expression of Egr-1 and its downstream target genes (TNF- α , IL-1 β ) or serum cTnI level. Collectively, these observations suggested that EA attenuates myocardial I/R injury, possibly through inhibiting the ERK1/2-Egr-1 signaling pathway and reducing the release of proinflammatory cytokines.
Insights
Electroacupuncture (EA) reduces heart injury after ischemia-reperfusion (I/R) by inhibiting the ERK1/2-Egr-1 pathway. This treatment lowers inflammatory cytokines and protects the heart from damage.
Area of Science:
- Cardiology
- Molecular Biology
- Inflammation Research
Background:
- Early growth response-1 (Egr-1) is a key regulator of inflammatory responses in myocardial ischemia-reperfusion (I/R) injury.
- Extracellular signal-regulated kinase 1 and 2 (ERK1/2) signaling activates Egr-1 and mediates the therapeutic effects of electroacupuncture (EA).
Purpose of the Study:
- To investigate whether EA reduces myocardial I/R injury and inflammation by inhibiting Egr-1 expression through the ERK1/2 pathway.
Main Methods:
- Mice underwent 1-hour myocardial ischemia and 3-hour reperfusion after pretreatment with EA, U0126 (an ERK1/2 inhibitor), or both.
- Evaluated Egr-1, phosphorylated-ERK1/2 (p-ERK1/2), inflammatory cytokines (TNF-α, IL-1β), infarct size, and cardiac troponin I (cTnI) levels.
Main Results:
- EA significantly reduced I/R-induced upregulation of Egr-1 and p-ERK1/2.
- EA decreased inflammatory cytokines, infarct size, and cTnI release.
- U0126 showed similar cardioprotective effects to EA, with no additive benefit when combined.
Conclusions:
- EA attenuates myocardial I/R injury by inhibiting the ERK1/2-Egr-1 signaling pathway.
- This inhibition reduces the release of proinflammatory cytokines, offering a potential therapeutic strategy for heart injury.

